Tag Archive for: Herpes Simplex Virus-2 vaccine

NanoBio to Present Data at ICAAC Supporting the Development of Safe and Effective RSV and Herpes Simplex Virus-2 Vaccines

Pre-clinical data demonstrates the ability of nanoemulsion-adjuvanted vaccines to provide immunogenicity and protection against illness and disease

ANN ARBOR, Mich., (September 11, 2013) – NanoBio Corporation today announced that the company will present new data at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting showing the safety and efficacy of a nanoemulsion (NE) adjuvanted intramuscular vaccine for the prevention of respiratory syncytial virus (RSV). RSV plagues nearly all children by the age of three and can be life-threatening for premature babies, children with other health conditions, and the elderly. Currently, a vaccine for the prevention of RSV is not commercially available. Read more